Penn Medicine researchers ran a 60-week trial in 120 adults who were overweight or had obesity, assigning them to once-weekly semaglutide at 2.4 mg or placebo, with regular lifestyle counseling in both groups
The prevalence of the 718TC and 718CC genotypes of the GPX4 gene was higher in the EHCS group as compared with the EH group (OR=2.12, 95%CI 1.423.16, P =0.0002, P adj =0.0018)
For someone with obesity, the cardiovascular risk reduction from losing 25% of their body weight almost certainly exceeds the risk from a 5 to 10 beat per minute resting heart rate increase
Secondly, translation of laboratory findings into clinical practice: while some GLP-1RAs have shown promise in regulating immune responses in preclinical studies, clinical implementation remains a major challenge
However, the enzyme NNMT disrupts this process
SeekPeptides has compiled the latest research, phase 3 results, and safety profiles so you can understand exactly what each drug offers and where each one falls short